Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk (NYSE: NVO) ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the ...

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is being ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Wegovy maker’s share price halves amid rising pressure from Eli Lilly and compounded copycats Novo Nordisk has removed its long-serving CEO, Lars Fruergaard Jørgensen, as the Danish pharmaceutical ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...